Announcements
- Abeona Therapeutics Provides Regulatory Update on Pz-cel
- Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA Inspections
- Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Announces $50 Million Credit Facility
- Abeona Therapeutics Announces FDA Accepts and Grants Priority Review for Pz-cel Biologics License Application (BLA)
- Abeona Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Developments
- Abeona Therapeutics Submits Biologics License Application to U.S. FDA Seeking Priority Review and Approval of EB-101 for the Treatment of Patients with Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer
- Abeona Therapeutics Announces Participation in Upcoming Investor Conferences
More ▼
Key statistics
As of last trade, Abeona Therapeutics Inc (0H7R:LSE) traded at 4.07, 40.15% above the 52 week low of 2.90 set on Aug 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 4.07 |
Average volume | 15.98k |
---|---|
Shares outstanding | 27.36m |
Free float | 25.40m |
P/E (TTM) | -- |
Market cap | 113.25m USD |
EPS (TTM) | -2.59 USD |
Data delayed at least 20 minutes, as of Apr 30 2024 19:09 BST.
More ▼